

CURRICULUM VITAE

ROBERT S. JANSSEN

BUSINESS Dynavax Technologies Corporation
ADDRESS: 2100 Powell Street, Suite 720
Emeryville, CA 94608
(510) 665-0414

WORK EXPERIENCE:

2018- Present Senior Vice President, Clinical Development, Medical and Regulatory Affairs and Chief Medical Officer, Dynavax Technologies

2013-2017 Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer, Dynavax Technologies

2010-2012 Senior Director, Clinical Development. Dynavax Technologies

2008-2010 Vice President, Medical Affairs. Gilead Sciences, Inc.

2000-2008 Acting Director/Director, Division of HIV/AIDS Prevention. National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC)

1987-2000 Various positions of increasing responsibility in HIV at CDC

EDUCATION:

M.D., University of Southern California School of Medicine, Los Angeles, CA

B.A., Honors in Humanities, Stanford University, Stanford, CA

POSTGRADUATE TRAINING:

Epidemic Intelligence Service Officer, Division of Viral Diseases, CDC

Postdoctoral Research Fellow in Neurovirology, University of Pennsylvania School of Medicine

Robert S. Janssen, M.D.

Resident in Neurology, Hospital of the University of Pennsylvania

Medicine Internship, Los Angeles County/University of Southern California Medical Center

SPECIALTY CERTIFICATION:

Neurology

US PUBLIC HEALTH SERVICE APPOINTMENT:

Captain (Retired)

AWARDS, HONORS:

US Department of Health and Human Services
2000 Secretary's Award for Distinguished Service (Early HIV Infection
Detection Team)

American Statistical Association
1999 Outstanding Statistical Application

CDC
1999 Charles Shepard Award for Excellence in Science
2008 Charles Shepard Award for Excellence in Science, Assessment and
Epidemiology

PUBLICATIONS:

Peer-reviewed Original Papers

1. Janssen RS, Kaye A, Lisak RP, Schatz N, Arger P, Savino P. Radiologic evaluation of the mediastinum in myasthenia gravis. *Neurology* 33:534-539, 1983.
2. Kaye AD, Janssen R, Arger PH, Lisak R, Coleman BG, Gefter W, Epstein D, Schatz NJ. Mediastinal computed tomography in myasthenia gravis. *J Comp Tomog* 7:273-279, 1983.
3. Beck R, Janssen R, Smiley L, Schatz N, Savino P, Rubin D. Bilateral third nerve palsies secondary to melioidosis. *Neurology* 34:105-107, 1984.

Robert S. Janssen, M.D.

4. Janssen R, Gonzalez-Scarano F, Nathanson N. Mechanisms of bunya virus virulence: Comparative pathogenesis of a virulent strain of La Crosse and an avirulent strain of Tahyna virus. *Lab Invest* 50:447-455, 1984.
5. Gonzalez-Scarano F, Janssen R, Najjar J, Pobjecky N, Nathanson N. An avirulent G1 glycoprotein variant of La Crosse bunyavirus with a defective fusion function. *J Virol* 54:757-763, 1985.
6. Janssen R, Nathanson N, Endres M, Gonzalez-Scarano F. The virulence of La Crosse virus is under polygenic control. *J Virol* 59:1-7, 1986.
7. Hedberg C, Fishbein D, Janssen R, Meyers B, McMillin J, MacDonald K, White K, Huss L, Hurwitz E, Fahrie J, Simmons J, Braverman L, Ingbar S, Schonberger L, Osterholm M. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. *N Engl J Med* 316:993-998, 1987.
8. Janssen R, Saykin A, Kaplan J, Spira T, Pinsky P, Sprehn G, Hoffman J, Mayer W Jr, Schonberger L. Neurologic complications of human immunodeficiency virus infection in patients with lymphadenopathy syndrome. *Ann Neurol* 23:49-55, 1988.
9. Gonzalez-Scarano F, Beaty B, Sundin D, Janssen R, Endres M, Nathanson N. Genetic determinants of the virulence and infectivity of La Crosse virus. *Microbial Pathog* 4:1-7, 1988.
10. The Rett Syndrome Diagnostic Criteria Work Group (Trevathan E, Moser HW, Opitz JM, Percy AK, Naidu S, Holm VA, Boring CC, Janssen RS, Yeargin-Allsopp M, Adams MJ). Diagnostic Criteria for Rett Syndrome. *Ann Neurol* 23:425-428, 1988.
11. Saykin A, Janssen R, Sprehn G, Kaplan J, Spira T, Weller P. Neuropsychological dysfunction in HIV-infection: characterization in a lymphadenopathy cohort. *Int J Clin Neuropsych* 1988;10:81-93.
12. Weinberg JB, Spiegel R, Blazey D, Janssen R, Robert-Guroff M, Matthews T, Haynes B, Palker T. A Cluster of HTLV-I seropositive individuals in North Carolina associated with "Smoldering" T-Cell leukemia. *Am J Med* 1988;85:51-58.
13. Levy R, Janssen R, Bush T, Rosenblum M. Neuroepidemiology of AIDS. *J Acquir Immune Defic Syndr* 1988;1:31-40.
14. Thadani V, Penar P, Partington J, Kalb R, Janssen R, Rabkin C, Schonberger L, Manuelidis E, Prichard J. Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. *J Neurosurg* 1988;69:766-9.

Robert S. Janssen, M.D.

15. Endres MJ, Jacoby DR, Janssen RS, Gonzalez-Scarano F, Nathanson N. The large viral RNA segment of California serogroup Bunyaviruses encodes the large viral protein. *J Gen Virol* 1989;70:223-8.
16. Janssen R, Saykin A, Kaplan J, Cannon L, Pinsky P, Campbell J, Hessol N, O'Malley P, Lifson A, Doll L. Neurological and neuropsychological manifestations of HIV infection: association with AIDS-related complex but not asymptomatic HIV-1 infection. *Ann Neurol* 1989;26:592-600.
17. Helmick CG, Wrigley JM, Zack MM, Bigler WJ, Lehman JJ, Janssen RS, Hartwig EC, Witte JJ. Multiple sclerosis in Key West, Florida. *Am J Epidemiol* 1989;130:935-949.
18. Osame M, Janssen R, Kubota H, Nishitani H, Igata A, Nagataki S, Mori M, Goto I, Shimabukuro H, Khabbaz R, Kaplan J. Nationwide survey of HTLV-I-associated Myelopathy in Japan: association with blood transfusion. *Ann Neurol* 1990;28:50-56.
19. Ingraham LJ, Bridge TP, Janssen RS, Stover E, Mirsky AF. Neuropsychological effects of early HIV-1 infection: assessment and methodology. *J Neuropsychiatr Clin Neurosci* 1990;2:174-182.
20. Kaplan J, Osame M, Igata A, Kubota H, Nishitani H, Khabbaz R, Janssen R. Risk of development of HTLV-I-associated myelopathy (HAM) among persons infected with HTLV-I. *J Acquir Immune Defic Syndr* 1990;3:1096-1101.
21. Kaplan J, Litchfield B, Rouault C, Lairmore M, Luo C, Williams L, Brew B, Price R, Janssen R, Stoneburner R, Ou C, Folks T, De B. HTLV-I-associated myelopathy associated with blood transfusion in the United States: epidemiologic and molecular evidence linking donor and recipient. *Neurology* 1991;41:192-197.
22. Janssen R, Cornblath D, Epstein L, McArthur J, Price R, and the American Academy of Neurology AIDS Task Force Working Group. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. *Neurology* 1991;41:778-785.
23. Saykin AJ, Janssen RS, Sprehn GC, Kaplan JE, Spira TJ, O'Connor B. Longitudinal evaluation of neuropsychological function in gay men HIV-1 infection: 18 month follow-up. *J Neuropsychiatr Clin Neurosci* 1991;3:286-298.
24. Janssen R, Kaplan J, Khabbaz R, Hammond R, Lechtenberg R, Lairmore M, Chiasson M, Punsalang A, Roberts B, McKendall R, Rosenblum M, Brew B, Farraye J, Howley D, Feraru E, Sparr S, Vecchio J, Silverman M, McHarg M, Gorin B, Rugg D, Grenell S, Trimble B, Bruining K, Guha S, Amaraneni P, Price R. HTLV-I-associated myelopathy/tropical spastic paraparesis in the United States. *Neurology* 1991;41:1355-1357.

Robert S. Janssen, M.D.

25. Gillespe S, Chang Y, Lemp G, Arthur R, Buchbinder S, Steimle A, Baumgartner J, Rando T, Neal D, Rutherford G, Schonberger S, Janssen R. Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, San Francisco, 1981-1989. *Ann Neurol* 1991;30:597-604.
26. Maj M, Janssen R, Satz P, Zaudig M, Starace F, Boor D, Sughondhabirom B, Bing E, Luabeya M, Ndeti D, Riedel R, Schulte G, Sartorius N. The World Health Organization's cross-cultural study on neuropsychiatric aspects of infection with the human immunodeficiency virus 1 (HIV-1): preparation and pilot phase. *Br J Psychiatr* 1991;159:351-356.
27. Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. *Neurology* 1991;41:1733-1736.
28. Perriens J, Mussa M, Luabeya M, Kayembe K, Kapita B, Brown C, Piot P, Janssen R. Neurological complications of HIV-1 seropositive internal medicine inpatients in Kinshasa, Zaire. *J Acquir Immune Defic Syndr* 1992;5:333-40.
29. Janssen RS, Nwanyanwu OC, Selik RK, Stehr-Green JK. Epidemiology of human immunodeficiency virus encephalopathy in the United States. *Neurology* 1992;42:1472-6.
30. Janssen RS, St. Louis ME, Satten G, Critchley SE, Petersen LR, Stafford RS, Ward JW, Hanson DL, Olivo N, Schable CA, Dondero TJ, the Hospital HIV Surveillance Group. HIV infection among patients in U.S. acute-care hospitals: strategies for the counseling and testing of hospital patients. *N Engl J Med* 1992;327:445-52.
31. Murrill CS, Kuncl KA, Weeks HA, Petersen LR, Janssen RS. HIV-1 seroprevalence in hospital patients in rural Georgia. *South Med J* 1992;85:969-71.
32. Maj M, D'Elia L, Satz P, Janssen R, Zaudig M, Uchiyama C, Starace F, Galderisi S, Chervinsky A. Evaluation of three new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1-seropositive persons: a WHO study. *Arch Clin Neuropsychol* 1993;8:123-135.
33. Maj M, Janssen R, Starace F, Zaudig M, Satz P, Sughondhabirom B, Luabeya M, Riedel R, Ndeti D, Calil H, St. Louis M, Sartorius N. WHO neuropsychiatric AIDS study, cross-sectional phase I. Study design and psychiatric findings. *Arch Gen Psychiatry* 1994;51:39-49.
34. Maj M, Satz P, Janssen R, Starace F, Zaudig M, D'Elia D, Sughondhabirom B, Mussa M, Bing EG, Naber D, Ndeti D, Schulte G, Sartorius N. WHO neuropsychiatric AIDS Study, cross-sectional phase II. Neuropsychological and neurological findings. *Arch Gen Psychiatry* 1994;51:51-61.

Robert S. Janssen, M.D.

35. Schwartlander B, Janssen RS, Satten GA, Critchley SE, Petersen LR, Dondero TJ. Guidelines for designing rapid assessment surveys of HIV seroprevalence among hospitalized patients. *Public Health Rep* 1994;109:53-59.
36. Nagachinta T, Brown CP, Cheng F, Temple W, Kerndt PR, Janssen RS. HIV-1 seroprevalence in an inner-city public hospital. *J Natl Med Assn* 1994;86:358-362.
37. Lemp GF, Hirozawa AM, Givertz D, Nieri GN, Anderson L, Lindegren ML, Janssen R, Katz M. HIV seroprevalence and risk behaviors among young gay and bisexual men: the San Francisco/Berkeley Young Men's Survey. *JAMA* 1994;272:449-454.
38. Wang F, So Y, Vittinghoff E, Malani H, Reingold A, Lewis E, Giordano J, Janssen R. Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis. *J Acquir Immune Defic Syndr* 1995;8:75-82.
39. Sweeney P, Lindegren ML, Buehler JW, Onorato IM, Janssen RS. Teenagers at Risk of Human Immunodeficiency Virus Type 1 Infection. *Arch Pediatr Adolesc Med* 1995;149:521-528.
40. Qureshi AI, Safdar K, Patel M, Janssen RS, Frankel MR. Stroke in young African American patients: risk factors, subtypes, and prognosis. *Stroke* 1995;26:1995-1998.
41. Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis WF, Notari EP, Petersen L. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. *N Engl J Med* 1995;333:1721-1725.
42. Irwin K, Olivo N, Schable CA, Weber T, Janssen R, Ernst J, and the CDC-Bronx Lebanon HIV Serosurvey Team. Performance characteristics of a rapid HIV antibody assay in a hospital with high prevalence of HIV infection. *Ann Intern Med* 1996;125:471-475.
43. Mackellar D, Valleroy L, Karon J, Lemp G, Janssen R. Methods for estimating prevalence in hard to reach groups. *Public Health Rep* 1996;111 (Supplement 1);138-144.
44. Irwin KL, Olivo N, Schable C, Weber JT, Janssen R, Ernst J. Absence of HIV-2 infection in a U.S. population at high risk for infection. *Transfusion* 1996;36:731-733.
45. Qureshi AI, Akbar MS, Czander E, Safdar K, Janssen RS, Frankel MR. Crack cocaine use and stroke in young patients. *Neurology* 1997;48:341-345.

Robert S. Janssen, M.D.

46. Katz M, Hsu L, Wong E, Liska S, Anderson L, Janssen R. Seroprevalence of and risk factors for hepatitis A infection among young homosexual and bisexual men. *J Infect Dis* 1997;175:1225-1229.
47. Herrera G, Lackritz E, Raimondi V, Janssen R. Serologic test for syphilis as a surrogate marker for human immunodeficiency virus infection among United States blood donors. *Transfusion* 1997;37:836-840.
48. Qureshi AI, Suri MA, Safdar K, Ottenlips JR, Frankel MR, Janssen RS. Intracerebral hemorrhage in blacks: risk factors, subtypes, and outcome. *Stroke* 1997;28:961-964.
49. Qureshi AI, Janssen RS, Karon JM, Weissman JP, Akbar K, Frankel MR. Human immunodeficiency virus infection and stroke in young patients. *Arch Neurol* 1997;54:1150-1153.
50. Irwin KL, Pau C-P, Lupo D, Pienazek D, Luo C-C, Olivo N, Rayfield M, Hu DJ, Weber JT, Respass RA, Janssen R, Minor P, Ernst J and the CDC-Bronx Lebanon HIV Serosurvey Team. Presence of HIV-1 subtype A infection in a New York community with high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America. *J Infect Dis* 1997;176:1629-1633.
51. Qureshi AI, Hanson DL, Jones JL, Janssen RS. Estimation of the temporal probability of HIV dementia after risk stratification in HIV-infected individuals. *Neurology* 1998;50:392-397.
52. Chin K, Sidhu JS, Janssen RS, Weber JT and the Sentinel Hospital Surveillance System for HIV Infection Principal Investigators. Prevalence of invasive cervical cancer among HIV infected and uninfected hospital patients, 1994-1995. *Obstetrics and Gynecology* 1998;92:83-87.
53. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, Hecht FM, Jack N, Cleghorn FR, Kahn JO, Chesney MA, Busch MP. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and public health purposes. *JAMA* 1998;280:42-48.
54. Valleroy LA, MacKellar DA, Karon JM, Janssen RS, Hayman CR. HIV infection in disadvantaged out-of-school youth: prevalence for U.S. Job Corps entrants, 1990 through 1996. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*. 1998;19:67-73.
55. Holman RC, Török TJ, Belay ED, Janssen RS, Schonberger LB. Progressive multifocal leukoencephalopathy in the United States, 1979-1994: Increased mortality associated with HIV-1-infection. *Neuroepidemiology* 1998;17:303-309.
56. Satten GA, Janssen R, Busch MP, Datta S. Validating marker-based incidence estimates in repeatedly screened populations. *Biometrics* 1999;55:254-257.

Robert S. Janssen, M.D.

57. McFarland W, Busch MP, Kellogg TA, Rawal BD, Satten GA, Katz MH, Dilley J, Janssen RS. Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. *JAIDS* 1999;22:484-489.
58. Valleroy LA, MacKellar DA, Karon JM, Rosen D, Janssen RS and Young Men's Survey Study. HIV prevalence and associated risks in young men who have sex with men. *JAMA* 2000; 284:198-204.
59. Otten RA, Smith D, Adams DR, Pullium JK, Jackson E, Kim CN, Jaffe H, Janssen R, Butera S, Folks T. Potent efficacy of post-exposure prophylaxis (PEP) 12 - 36 hours after intravaginal exposure of pig-tailed macaques with a human-derived retrovirus (HIV-2). *J Virol* 2000;74:9771-9775.
60. MacKellar D, Valleroy LA, Hoffmann JP, Glebatis D, LaLota M, McFarland W, Westerholm J, Janssen RS. Gender differences in sexual behaviors and factors associated with nonuse of condoms among homeless and runaway youths. *AIDS Education and Prevention* 2000; 12:477-491.
61. Parekh BS, Hu DJ, Vanichseni S, Satten GA, Candal D, Young NL, Kitayaporn D, Srisuwanvilai LO, Rakhtam S, Janssen R, Choopanya K, Mastro TD. Evaluation of a Sensitive/Less-Sensitive Testing Algorithm Using the 3A11-LS Assay for Detecting Recent HIV Seroconversion among Individuals with HIV-1 Subtype B or E Infection in Thailand. *AIDS Res Hum Retroviruses*.2001;17:453-458.
62. MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, Ford W, LaLota M, Celentano DD, Koblin BA, Torian LV, Thiede H, Janssen RS, for the Young Mens Survey Group. Two decades after vaccine license: Hepatitis B virus infection among young men who have sex with men. *AJPH* 2001;91:965-71.
63. Pullium JK, Adams DR, Jackson E, Kim CN, Smith DK, Janssen R, Gould K, Folks TM, Butera S, Otten RA. Pig-tailed macaques infected with HIV-2_{GB122} or SHIV_{89.6p} express virus in semen during primary infection: new model for genital tract shedding and transmission. *JID* 2001;183:1023-1030.
64. Moore A, Herrera G, Nyamongo J, Granade T, Nahlen B, Lackritz E, Janssen R. Estimated Incidence of HIV by Blood Transfusion in Kenya. *Lancet* 2001;358:657-660.
65. Janssen RS, Holtgrave DR, Valdiserri RO, Shepherd M, Gayle HD, De Cock KM. Serostatus Approach to Fighting the HIV Epidemic: Prevention Strategies for HIV-infected individuals. *AJPH* 2001; 91:1019-1024.
66. MacKellar DA, Valleroy LA, Secura GM, Bartholow BN, McFarland W, Shehan D, Ford W,

Robert S. Janssen, M.D.

LaLota M, Celentano DD, Koblin BA, Torian LV, Perdue TE, Janssen RS, for the Young Men's Survey Study Group. Repeat HIV Testing, Risk Behaviors, and HIV Seroconversion Among Young Men Who Have Sex With Men. *JAIDS* 2002;29:76-85.

67. Quan VM, Steketee RW, Valleroy L, Weinstock H, Karon J, Janssen R. HIV incidence in the United States: 1978-1999. *JAIDS* 2002;31:188-201.

68. Weinstock H, Dale M, Gwinn M, Satten GA, Kothe D, Mei J, Royalty J, Linley L, Fridlund C, Parekh B, Rawal BD, Busch MP, Janssen RS. HIV seroincidence among patients at clinics for sexually transmitted diseases in 9 cities in the United States. *JAIDS* 2002;29:478-83.

69. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS, and the HIV Outpatient Study (HOPS) Investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. *Lancet* 2002;360:1747-48.

70. Kothe D, Byers B, Caudill S, Satten G, Janssen R, Hannon H, Mei J. Performance characteristics of a new less-sensitive HIV-1 EIA for use in estimating HIV seroincidence. *JAIDS* 2003; 33: 625-634.

71. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, Nelson R, Mock PA, Choopanya K, Janssen R, Mastro TD, Mei JV. Evaluation of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B or E infection in Thailand. *AIDS Research and Human Retroviruses* 2003;19:481-486.

72. Lee L, McKenna M, Janssen R. Classification of transmission risk in the national HIV/AIDS surveillance system. *Pub Health Report*. 2003;118:400-407.

73. Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, Sheppard HW, Busch MP. Development of a New Less-Sensitive Enzyme Immunoassay for Detection of Early HIV-1 Infection. *JAIDS* 2003;33:349-55.

74. Valdiserri RO, Odgen LO, Janssen RS, Onorato IM, Martin T. Aligning budget with US national HIV prevention priorities. *J Public Health Management and Practice*. *J Pub Health Manage Prac* 2004;10:140-147.

75. MacKellar DA, Valleroy LA, Secura GM, Behel S, Bingham T, Celentano DD, Koblin BA, LaLota M, McFarland W, Shehan D, Thiede H, Torian LV, Janssen RS. Unrecognized HIV infection, risk behaviors, and perceptions of risk among young men who have sex with men. *JAIDS* 2005;38:603-614.

76. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV: implications for HIV prevention programs. *JAIDS* 2005;39:446-453.

Robert S. Janssen, M.D.

77. MacKellar DA, Valleroy LA, Anderson JE, Behel S, Secura GM, Bingham T, Celentano DD, Koblin BA, LaLota M, Shehan D, Thiede H, Torian LV, Janssen RS. Recent HIV testing among young men who have sex with men: correlates, contexts, and HIV seroconversion. *Sexually Transmitted Disease* 2006; 33:183-192.

78. Subbarao D, Otten R, Ramos A, Jackson E, Monsour M, Bashirian S, Kim C, Johnson J, Soriano V, Hudgens MG, Butera S, Janssen R, Paxton L, Greenberg A, Folks T. Pre-exposure prophylaxis with tenofovir disoproxil fumarate protected rhesus macaques against infection from multiple rectal virus challenges but ultimately did not prevent infection. *JID* 2006;194:904-11.

79. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware they are infected with the virus in the United States. *AIDS* 2006; 20:1447-1450.

80. Fairchild AL, Gable L, Gostin LO, Bayer R, Sweeney P, Janssen R. Public goods, private data: HIV and the history, ethics, and the uses of personally identifiable public health information. *Public Health Rep* 2007;122(suppl):1-18.

81. Janssen RS. HIV Screening. *Clin Infect Dis* 2007;45(Suppl 4):S226-S231.

82. McNaghten AD, Wolfe M, Onorato I, Nakashima AK, Romaguera RA, Valdiserri RO, Janssen R, Krolczak A, Mokotoff E, Sullivan PS. Improving the representativeness of clinical and behavioral surveillance for persons with HIV in the United States: the rationale for developing a population-based approach. *PLoS ONE* 2007(6): e550.
doi:10.1371/journal.pone.0000550.

83. Garcia-Lerma G, Otten R, Qari S, Cong ME, Kim C, Monsour M, Schinazi R, Janssen R, Folks T, Heneine W. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. *PLoS Medicine*. 5(2):e28, 2008 Feb.

84. Hall HI, Song R, Rhodes P, Prejean J, An Q, McKenna M, Janssen R and the HIV Incidence Surveillance Group. HIV incidence in the United States, 2006. *JAMA* 2008;300:520-529.

85. Hall HI, Geduld J, Boulos D, Rhodes P, An Q, Mastro TD, Janssen RS, Archibald CP. Epidemiology of HIV/AIDS in the USA and Canada: current status and ongoing challenges. *JAIDS*. 2009;51(Suppl 1):S13-20.

86. Kuan RK, Janssen RS, Heyward WL, Nordyke R. The cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in adults with diabetes, adults with chronic or end stage kidney disease, health care workers and international travelers. *Vaccine* 2013;31:4024-32.

87. Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine

Robert S. Janssen, M.D.

with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. *Vaccine* 2013;31:5306-5313.

88. Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett SR, Janssen RS, Namini H, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40 to 70 years of age. *Vaccine* 2013;31:5300-5305.

89. Janssen JM, Martin JT, Janssen RS. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. *Vaccine* 2015;33:833-837.

90. Janssen JM, Jackson S, Heyward WL, Janssen RS. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18 – 70 years of age. *Vaccine* 2015;33:3614-3618.

91. Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, Shockey G, Akella L, Erby K, Heyward WL, Janssen RS, and the HBV-23 Study Team. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a Toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. *Vaccine* 2018;36:668-674.

92. Hyer R, McGuire D, Xing B, Jackson S, and Janssen RS. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a Toll-like receptor 9 agonist adjuvant in adults. *Vaccine* 2018;36:2604-2611.

93. Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick J, Barve M, Daniels GA, Wong DL, Schmidt EV, Candia AF, Coffman R, Leung ACF, and Janssen R. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase 1b, multicenter study. *Cancer Discovery* 2018;8:1250-1257.

94. Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Janssen R, Candia A, Coffman RL, Levy R. In situ vaccination with the TLR9 agonist, SD-101, in combination with local low dose radiation induces systemic responses in previously untreated indolent B-cell lymphoma. *Cancer Discovery* 2018;8:1258-1269.

95. Hyer R and Janssen RS. Immunogenicity and safety of two-dose hepatitis B vaccine, HBsAg/CpG-1018, in persons with diabetes mellitus aged 60 years or older. *Vaccine* 2019; 37:5854-61.

Robert S. Janssen, M.D.

96. Bruxvoort K, Slezak J, Huang R, Ackerson B, Sy L, Qian L, Reynolds K, Towner W, Solano Z, Mercado C, Hyer R, Janssen R, Jacobsen SJ. Association of number of doses with hepatitis B vaccine series completion in US adults. *JAMA Network Open* 2020;3(11):e2027577.

97. Garon E, Spira AI, Johnson M, Bazhenova L, Leach J, Cummings AL, Candia A, Coffman RL, Janatpour MJ, Janssen R, Gamelin E, Chow LQM. A phase 1b/2, open label, multicenter study of inhaled DV281, a Toll-like receptor 9 agonist, in combination with nivolumab in patients with second- or third-line advanced or metastatic non-small cell lung cancer. *Clin Cancer Res* 2021;27:4566-73.

98. Awad AM, Ntoso A, Connaire JC, Hernandez GT, Dhillon K, Rich L, Henderson H, Lynn R, Hyer RN, Xie F, Erby K, Janssen RS for the HBV-24 Study Group. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis. *Vaccine* 2021;39:3346-52.

99. Hirst A, Hyer R, Janssen R. Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in select adult populations. *Vaccine* 2021;39:4733-41.

100. Hsieh SM, Liu WD, Huang YS, Lin YJ, Hsieh EF, Lian WC, Chen C, Janssen R, Tai IC, Chang SC. Safety and immunogenicity of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine (MVC-COV1901) with adjuvant of aluminum hydroxide and CpG 1018 in healthy adults: a phase 1, dose-escalation study. *EClinicalMedicine* 2021;38:100989.

101. Janssen R, Bruxvoort K, Jacobsen S, Slezak J, David C, Hyer R, Poland G. Considerations for estimating real-world outcomes and value in vaccination: a case study with adult hepatitis B virus vaccination. *Vaccine* 2021;39:5666-72.

102. Cohen E, Nabell L, Ribas A, Day T, Daniels G, Milhem M, Deva S, Jameson M, Guntinas-Lichius O, Almubarak M, Stroher M, Whitman E, Chisamore M, Obiozor C, Bagulho T, Guiducci C, Gamelin E, Janssen R, Algazi A. Phase 1b/2, open-label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment-naïve patients with recurrent or metastatic head and neck squamous cell carcinoma. *Clin Cancer Res* 2022; 28:1157-1166.

103. Kushner T, Huang V, Janssen R. Safety and immunogenicity of HepB-CpG in women with documented pregnancies during HepB-CpG clinical trial follow up. *Vaccine* 2022; 40:2899-2903.

104. Estrada JA, Cheng C-Y, Ku S-K, Hu HC, Yeh H-W, Lin Y-C, Chen C-P, Cheng S-H, Janssen RS, and Lin I-F. An immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChA-dOx1-nCov-19 (AstraZeneca) or MVC-COV1901. *Vaccines* 2022; 10:655.

Robert S. Janssen, M.D.

105. Oster G, Bornheimer R, Ottino K, Stevenson C, Janssen R, Lewin C. Adult immunization against hepatitis B: Does the number of jabs matter? *Vaccine* 2022; 40:(3597-3604).

106. Lien CE, Waits A, Chen JY, Cheng WH, Yeh JI, Hsieh SM; Chen C; Janssen R, Lin TY. Safety and immunogenicity of MVC-COV1901 vaccine in older adults: phase 2 randomized dose-comparison trial. *Int JID* 2022;124:21-26.

107. Girndt M, Dellanna F, Stankewitsch-Dederichs E, Bosselmann HP, Beige J, Plier M, Haller H, Koch M, Hyer R, Janssen R. An open-label, randomized, multi-center study comparing the safety and immunogenicity of HEPLISAV-B to Engerix-B and Fendrix in adults on hemodialysis who have previously received hepatitis B vaccination and are not seroprotected. *Hum Vaccines Immun* 2022; 18: 6, 2136912.

108. Torales J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, Estigarribia G, Sanabria G, Lin MY, Estrada J, Estephan L, Cheng HY, Chen C, Janssen R, Lien CE. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay. *Vaccine* 2022; <https://doi.org/10.1016/j.vaccine.2022.10.030>.

109. Girndt M, Houser P, Mangoo-Karim R, Ervin JE, Charytan C, Chow S, Diamond S, Silver M, Lehrner L, Hart R, Wombolt D, Linfert D, Shemin D, Michelsen A, Xie F, Janssen RS. Long-term immunogenicity and safety of a hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HepB-CpG) compared with a hepatitis B vaccine with an alum adjuvant in patients with chronic kidney disease. *Vaccine* 2023; 41: 3224-3232.

Book Chapters, Letters to the Editor, and Invited Papers:

1. Levy R, Janssen R, Bush T, Rosenblum M. Neuroepidemiology of AIDS. In: *AIDS and the Nervous System*. Rosenblum M, Levy R, Bredesen D, eds. New York: Raven Press, 1987:13-27.

2. Janssen R, Saykin A, Kaplan J, Spira T, Pinsky P, Sprehn G, Hoffman J, Mayer W Jr, Schonberger L. Neurologic symptoms and neuropsychologic abnormalities in lymphadenopathy syndrome. Presented at *Retroviruses and the Nervous System*, NIH, Bethesda, MD. May 1987: *Ann Neurol* 23(suppl): S17-18, 1988.

3. Janssen R. Neurological aspects of HIV infection. In *Report of the Third National Conference on AIDS (Australia)*. Canberra: Australian Government Publishing Service, 1988:336-44.

4. Janssen R. HIV and the Nervous System. In *AIDS: Principles, Practices and Politics*. Corless I, Pittman-Lindeman M, eds. Washington, DC: Hemisphere Publishing Co., 1989:55-60.

Robert S. Janssen, M.D.

5. Janssen R, Cornblath D, Epstein L, McArthur J, Price R. Human immunodeficiency virus (HIV) infection and the nervous system: report from the American Academy of Neurology AIDS Task Force. *Neurology* 1989;39:119-22.
6. Janssen R, Schonberger L. Creutzfeldt-Jakob Disease from allogeneic dura: a review of risks and safety (discussion). *J Oral Maxillofac Surg* 1991;49:274-275.
7. Budka H, Wiley CA, Kleihues P, Artigas J, Asbury AK, Cho E-S, Cornblath DR, Dal Canto MC, DeGirolami U, Dickson D, Epstein LG, Esiri MM, Giangaspero F, Gosztonyi G, Gray F, Griffin JW, Hénin D, Iwasaki Y, Janssen RS, Johnson RT, Lantos PL, Lyman WD, McArthur JC, Nagashima K, Peress N, Petito CK, Price RW, Rhodes RH, Rosenblum M, Said G, Scaravilli F, Sharer L, Vinters HV. HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. *Brain Pathol* 1991;1:142-150.
8. Janssen R. Epidemiology of neurologic complications of HIV infection. *Proceedings of the XIVth World Congress of Neurology*. Amsterdam, Netherlands: Elsevier Science Publishers B.V. 1991.
9. Janssen R, McArthur J. HIV Nomenclature (Reply to Letter to the editor). *Neurology* 1992;42:265.
10. Janssen R. Epidemiology of human immunodeficiency virus infection and the neurologic complications of the infection. *Seminars in Neurology* 1992;12:10-17.
11. Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC. PML in AIDS (Reply to Letter to the editor). *Neurology* 1992;42:1845-6.
12. Janssen R, Petersen L, Ward J. Undiagnosed HIV infection in acute care hospitals. (Reply to Letter to the Editor). *N Engl J Med* 1992;327:1815-6.
13. Janssen RS, Bolyard EA. Considerations for programs for routine, voluntary HIV counseling and testing of patients admitted to acute-care hospitals. In *AIDS Testing*, G Schochetman and JR George, eds. Springer-Verlag, 2nd ed. 1994:245-251.
14. Petersen LR, Gwinn ML, Janssen RS, Satcher D, Dowdle WR, Curran JC, Hughes JM, Jaffe HW, Forrester WR, Morgan WM, McGaughey S. National HIV Serosurveillance Summary: Results through 1992. Vol 3. Atlanta, GA:U.S. Department of Health and Human Services;1994.
15. Weber JT, Janssen RS, George JR, Ward JW. The cost-effectiveness of voluntary counseling and testing of hospital patients for HIV (letter). *JAMA* 1995;274:129-130.
16. Janssen RS. Epidemiology and neuroepidemiology of HIV infection. In: *AIDS and the Nervous System*. Berger J, Levy, R, eds. Philadelphia: Lippincott-Raven Publishers, 2nd ed.

Robert S. Janssen, M.D.

1996: 13-37.

17. Satz P, Myers HF, Maj M, Fawzy F, Forney DL, Bing EG, Richardson MA, Janssen R. Depression, substance use and sexual orientation as co-factors in HIV-1 infected men: cross-cultural comparisons. *NIDA Res Monogr* 1997;172:130-155.

18. Fleming PL, Wortley PM, Karon JM, De Cock KM, Janssen RS. Tracking the HIV epidemic: current issues, future challenges. *AJPH* 2000;90:1037-1041.

19. Paxton L, Janssen R. The epidemiology of HIV infection in the era of HAART. *Journal of HIV Therapy* 2000;5:2-4.

20. Valdiserri RO, Janssen RS, Buehler JW, Fleming PL. The context of HIV/AIDS surveillance. *JAIDS* 2000;25:S97-S104.

21. Satten GA, Janssen RS, Stramer S, Busch MP. Development and validation of a serologic testing algorithm for recent HIV seroconversion (STARHS). In: Quantitative evaluation of HIV prevention programs. Eds: Edward H. Kaplan and Ron Brookmeyer. New Haven, Conn.: Yale University Press 2001 (in press).

22. Paxton L, De Cock K, Janssen RS. HAART and HIV Prevention. In: HIV Prevention. Ed: Ann O'Leary. 2001 (in press).

23. DeCock K, Janssen R. An unequal epidemic in an unequal world.(editorial) *JAMA* 2002;288:236-238.

24. Wolitski RJ, Janssen RS, Holgrave DR, Peterson JL. The public health response to the HIV epidemic in the United States. In: *AIDS and Other Manifestations of HIV Infection*. Fourth edition. Ed: Gary P Wormser. Elsevier (USA). 2004:997-1012.

25. Janssen R. A new RX for HIV prevention. *Physician's Weekly* 2004;XXII.

26. Janssen RS. The challenge of HIV testing. *Internal Med News* 2004;37.

27. Janssen RS, Valdiserri RO. HIV Prevention in the United States: Increased emphasis on working with those living with HIV. *JAIDS* 2004;37:S119-S121.

28. Wolitski RJ, Janssen RS, Onorato IM, Purcell DW, Crepaz N. An overview of prevention with people living with HIV. In: *Positive Prevention*. Ed: S Kalichman. Kluwer Academic/Plenum Publishers. 2005:1-28.

29. Byers, Robert H. Dale J. Hu Robert S. Janssen. Estimating HIV Incidence from a Cross-sectional Survey with the Less-Sensitive Assay . In: *Deterministic and Stochastic Models of*

Robert S. Janssen, M.D.

AIDS Epidemics and HIV Infections with Intervention. Ed: Wai-Yuan Tan and Hulin Wu. Singapore: World Scientific Publishing. 2005;513-524.

30. Janssen R, McKenna M. Cost effectiveness of HIV prevention interventions. (Letter to the Editor). Health Affairs 2005;24:1683.

31. Greenberg A, Drotman P, Curran J, Janssen RS. The epidemiology and prevention of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). In: Public Health and Preventive Medicine. 15th edition. Ed: Robert B. Wallace. Appleton and Lange. 2005. 189-199.

32. Buchacz K, Greenberg A, Onorato I, Janssen R. Syphilis epidemics and HIV incidence among men who have sex with men (MSM) in the United States: Implications for prevention. STD 2005;32(suppl):S73-S79.

33. Sullivan PS, McKenna ML, Janssen RS. Progress towards implementation of integrated systems for surveillance of HIV infection and morbidity in the United States. Public Health Rep. 2007;122(suppl 1): 1-3.

34. Janssen R. HIV testing: rationale for changing recommendations. Top HIV Med 2007;15:6-10.

35. Dooley S, Douglas J, Janssen R. Partner Counseling and Referral Services. Now is the time. Am J Prev Med 2007;33(Suppl 1):S81-S83.

36. Branson B, Janssen R. Response to Holtgrave, DR "Cost and consequences of the US CDC's recommendations for opt-out HIV testing." PLoS Medicine Vol. 4, No. 6, e194 doi:10.1371/journal.pmed.0040194 (19 November 2007).

Morbidity and Mortality Weekly Report and Other CDC Publications:

1. CDC. Rapidly progressive dementia in a patient who received a cadaveric dura mater graft. MMWR 1987;36:49-50,55.

2. CDC. Update: Creutzfeldt-Jakob disease in a patient receiving a cadaveric dura mater graft. MMWR 1987;36:324-5.

3. CDC. Update: Creutzfeldt-Jakob disease in a second patient who received a cadaveric dura mater graft. MMWR 1989;38:37-8,43.

4. Ward JW, Janssen RS, Jaffe HW, Curran JW. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings. MMWR 1993;42(No. RR-2):1-6.

Robert S. Janssen, M.D.

5. Janssen R, Neal J. Suggested Guidelines for Developing an Epidemiologic Profile for HIV Prevention Community Planning. CDC. June 1995.
6. Lackritz EM, Janssen RS, Gayle HD, Schable CA, Jaffe HW, Epstein JS, Mied PA, Geyer SJ. U.S. Public Health Service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type 1 antigen. *MMWR* 1996;45(No. RR-2):1-9.
7. Smith DK, Janssen RS, Holtgrave DR, De Cock KM, Goosby EP, Black RJ, Francis HL, Hoff R, Struble KA, Pratt RD, Parham DL. Statement on management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. *MMWR* 1998;47(No. RR-17):1-14.
8. CDC. HIV tests among persons using anonymous or confidential HIV counseling and testing in federally funded testing sites—United States, 1995-1997. *MMWR* 1999;48:509-513.
9. Fleming PL, Ward JW, Janssen RS, De Cock KM, Valdiserri RO, Gayle HD. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. *MMWR* 1999;48(No. RR-13): 1-31.
10. Bingham T, McFarland W, Shehan DA, LaLota M, Celentano DD, Koblin BA, Torian LV, MacKellar DA, Valleroy LA, Secura GS, Janssen RS. Unrecognized HIV infection, risk behavior, and perceptions of risk among young black men who have sex with men—six U.S. cities, 1994-1998. *MMWR* 2002;51:733-736.
11. Brener N, Lowry R, Kann L, Kolbe L, Wilcox LS, Janssen RS, Nowicki-Lehnherr C. Trends in sexual risk behaviors among high school students, United States, 1991-2001. *MMWR* 2002;51:856-859.
12. Janssen RS, Onorato IM, Valdiserri RO, Durham TM, Nichols WP, Seiler EM, Jaffe HW. Advancing HIV Prevention: new strategies for a changing epidemic in the United States, 2003. *MMWR* 2003;52:329-332.
13. Wolitski RJ, Henny KD, Lyles CM, Purcell DW, Carey JW, Crepaz N, O'Leary A, Mastro TD, Cleveland JC, Nakashima AK, Janssen RS. Evolution of HIV/AIDS prevention programs—United States, 1981–2006. *MMWR* 2006;55(21):597-603.
14. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR* 2006;55(RR-14):1-17.
15. Mast EE, Weinbaum C, Fiore AE, Alter MJ, Rodewald LE, Douglas JM, Janssen RS, Ward JW. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. *MMWR* 2006;55(RR-16):1-25.

Robert S. Janssen, M.D.

16. Durant T, McDavid K, HU X, Sullivan P, Janssen R, Fenton K. Racial/ethnic disparities in diagnoses of HIV/AIDS—33 states, 2001-2005. *MMWR* 2007;56:189-193.